MDM2 and neuroblastoma: Additionally, MYCN-amplified neuroblastoma cells treated with MDM2 antagonists, nutlin-3 and MI-63, had decreased cell proliferation when compared to MYCN-unamplified cells, further illuminating the importance of the relationship between MYCN and P53 in neuroblastoma [65].